Investor Relations

Chat with us!


companies joined our platform in the last 12 months

0 +

talents working day by day to fulfill our vision

0 M€

in proforma consolidated revenue in 2020

Welcome to our Investor Relations Portal

Chronic pain, stress and sleep issues affect the health and well-being of millions of people – proper solutions to these problems reflect multi-billion dollar markets.

SynBiotic is a biotech & health platform striving to challenge the status quo and bring innovation to the solution of these global problems. With our buy & build strategy, we cover the whole value chain and transform the healing power of cannabinoids & terpenes into better solutions for complex problems

About the Stock

  • Basic Information
  • Stock Chart
  • Shareholder Structure
  • Analysts


ISIN: DE000A3E5A59

Ticker Symbol: SBX

Stock Exchange: Xetra, Düsseldorf, Tradegate, GETTEX

Total number of shares: 3.674.000

Share capital: 3.674.000,00 EUR 

Analyst                                         Recommendation          Target Price      Last Research

Hauck & Aufhäuser                        BUY                                     75 EUR              October 2021

Edison Investment Research         Initiation                                                     July 2021

Alster Research                                BUY                                     37 EUR              September 2021

Baader Bank                                    BUY                                     40 EUR             October 2021

About the Company

  • Vision
  • Organs
  • Analyst Presentation


Vision:                 Europe's #1 ecosystem for solutions based on
                             cannabinoids and terpenes

Mission:               We are building Europe's largest ecosystem for cannabinoid & terpene                               
                             based solutions and transform ideas into better brands &                                           
                             Products for multi-billion markets like pain, sleep & anxiety.

Growth:               We grow 75% year on year (20% organic, 55% inorganic).

Strategy:             We cover the entire cannabinoid value chain with our buy & build strategy and
                              consolidate the strongest players in the industry under one roof. SynBiotic SE is divided into the
                              following verticals:

                              1) D2C & medical brands  
                              2) Production & Biotech
                              3) Research & Development 

SynBiotic with the legal form SE (European Company or Societas Europaea) has a monistic management model ("one-tier system"). In the monistic system, the management is not institutionally separated from the supervision. Rather, these two functions are performed by one and the same body (board of directors, administrative board).


Executive Director


Serial entrepreneur with over 10 years of experience in scaling profitable businesses. Deep industry expertise from seed to shelf, genetics, extraction methods & analytics like product development. He has been in the cannabinoid industry since 2015.



Board of Directors

Chairman of the Board of Directors:

As a serial entrepreneur, his strengths lie in strategy, ops and executive coaching, with particular expertise in post-merger integration and capital market fitness. Sebastian holds a Master's degree in Business Administration with a focus on IT-enabled marketing and human resources.








Member of the Board of Directors

Dr. Marlon Braumann is a serial entrepreneur and one of the founding partners of the European VC fund Elevat3 Capital - an investment fund primarily focused on biotech, medtech and fintech investments. In addition, Mr. Braumann is the founder of the global wildlife foundation AMES Foundation



Member of the Board of Directors

Mr. Hanke has extensive transaction experience (private equity, venture capital, growth capital & PIPE transactions) and has held various interim operational mandates in portfolio management in addition to his investor activities.

SynBiotic SE - Anayst Presentation (July 2021): Download


  • Ad-hoc-Releases
  • Corporate News
  • Financial Reports
  • Other Documents

Annual General Meetings

  • 2021
  • 2020
  • Financial Dates

Annual General Meeting on August 05, 2021.

The Annual General Meeting of SynBiotic SE took place on Thursday, August 5, 2021, at 10:00 a.m. (CEST).


The Company's Annual General Meeting was held as a virtual general meeting without the physical presence of shareholders or their proxies (except for the Company's proxies).


There were no countermotions.


  • July 2022 | Publication of the financial statements 2021
  • August 2022 | Annual General Meeting

SynBiotic Newsletter

Please use our e-mail order service to register your details so we can keep you updated with current information on our company such as corporate news or financial reports. We will handle your personal information for processing your request. Fields marked with * have to be filled.


If you have any further questions, please do not hesitate to contact us. You can reach us by e-mail or directly on the phone. In addition, we will be happy to include you in our IR news service. This way, you will directly receive all information on investor relations topics of SynBiotic SE. For voting rights notifications to the company, please use the contact details below.


SynBiotic SE
Barer Str. 7 
80333 München


Johannes Fontner, M.A.
Finance & Investor Relations